phrykt

Editas Medicine, Inc. (EDIT): who owns it and who trades it

As of Nov 16, 2026, EDIT insiders reported 16 open-market sales worth $177K and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Gilmore Neil O'Neill (CEO), with $131K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Editas Medicine

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns EDIT

213 funds and institutions reported EDIT shares worth $392M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is TCG Crossover Management, LLC with 11.3%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

TCG Crossover Management, LLC11.3%
BlackRock, Inc.10.8%
ADAR1 Capital Management, LLC9.1%
Ra Capital Management, L.P.9.1%
Commodore Capital LP9.1%
Vanguard Capital Management LLC6.3%
Paradigm Biocapital Advisors LP5.7%
Opaleye Management Inc.3.9%
Vanguard Portfolio Management LLC3.7%
Woodline Partners LP3.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
TCG Crossover Management, LLC11.11M11.35%$36M–
BlackRock, Inc.10.59M10.82%$34.3M+14%
ADAR1 Capital Management, LLC8.89M9.08%$28.8M–
Ra Capital Management, L.P.8.89M9.08%$28.8M–
Commodore Capital LP8.89M9.08%$28.8M–
Vanguard Capital Management LLC6.14M6.27%$19.9M+46%
Paradigm Biocapital Advisors LP5.59M5.71%$18.1M–
Opaleye Management Inc.3.86M3.94%$12.5M+100%
Vanguard Portfolio Management LLC3.60M3.68%$11.7M+14%
Woodline Partners LP3.56M3.63%$11.5M–
Vivo Capital, LLC3.56M3.63%$11.5M–
GordonMD Global Investments LP3.13M3.19%$10.1M–
Goldman Sachs Group Inc2.61M2.67%$8.5M+368%
Geode Capital Management, LLC2.57M2.62%$8.3M+11%
Renaissance Technologies LLC2.47M2.52%$8M-38%
Logos Global Management LP2.22M2.27%$7.2M–
State Street Corp2.19M2.24%$7.1M+6%
Marshall Wace, LLP2.04M2.08%$6.6M+869%
D. E. Shaw & Co., Inc.1.90M1.94%$6.2M-2%
JPMorgan Chase & Co1.86M1.90%$6M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, EDIT insiders reported $0 of open-market purchases and $177K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$177K
16 trades, 3 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 13, 2026

Purchases and sales by month

$70K$70KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026Linda BurklyVice presidentSale plan7,814$2.42$18.9KForm 4
Nov 11, 2026Gilmore Neil O'NeillCEOSale plan21,164$2.42$51.1KForm 4
Sep 3, 2026Linda BurklyVice presidentSale plan709$3.04$2.2KForm 4
Sep 3, 2026Amy ParisonCFOSale plan453$3.04$1.4KForm 4
Sep 3, 2026Gilmore Neil O'NeillCEOSale plan5,124$3.04$15.6KForm 4
Aug 3, 2026Amy ParisonCFOSale plan678$2.58$1.7KForm 4
Jul 28, 2026Linda BurklyVice presidentSale plan4,928$2.67$13.2KForm 4
Jun 3, 2026Amy ParisonCFOSale plan464$2.70$1.3KForm 4
Jun 3, 2026Gilmore Neil O'NeillCEOSale plan15,380$2.70$41.5KForm 4
Jun 3, 2026Linda BurklyVice presidentSale plan731$2.70$2KForm 4
Mar 3, 2026Gilmore Neil O'NeillCEOSale plan5,394$2.02$10.9KForm 4
Mar 3, 2026Amy ParisonCFOSale plan474$2.02$957Form 4
Mar 3, 2026Linda BurklyVice presidentSale plan749$2.02$1.5KForm 4
Dec 3, 2025Linda BurklyVice presidentSale plan713$2.15$1.5KForm 4
Dec 3, 2025Gilmore Neil O'NeillCEOSale plan5,603$2.15$12KForm 4
Dec 3, 2025Amy ParisonCFOSale plan461$2.15$991Form 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Gilmore Neil O'NeillCEO, Director–$131KNov 11, 2026
Linda BurklyEVP, CHIEF SCIENTIFIC OFFICER–$39.2KNov 11, 2026
Amy ParisonSVP, Chief Financial Officer–$6.3KSep 3, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

EDIT short interest

Very high short interest. 25.2% of EDIT shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 305%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 38.72M EDIT shares were sold short, 25.2% of the shares outstanding, up 1.4% from the report before. At the average daily volume of 2.20M shares, buying them all back would take about 17.6 trading days (days to cover).

Shares short, % of all shares

25.2%May 15Oct 3027.5%

Days to cover

17.6May 15Oct 3020.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202638.72M25.21%+1%2.20M17.6
Oct 15, 202638.19M24.86%+3%2.66M14.3
Sep 30, 202637.11M24.16%+24%3.97M9.3
Sep 15, 202629.96M19.51%-1%1.91M15.7
Aug 31, 202630.23M19.69%+22%3.37M9.0
Aug 14, 202624.69M16.07%+5%1.69M14.6
Jul 31, 202623.46M15.28%+6%1.29M18.2
Jul 15, 202622.20M22.67%-1%2.77M8.0
Jun 30, 202622.47M22.95%+22%3.12M7.2
Jun 15, 202618.41M18.81%+22%2.39M7.7
May 29, 202615.07M15.39%+58%4.48M3.4
May 15, 20269.56M9.77%-4%1.12M8.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Editas Medicine company events

Editas Medicine filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, auditor). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Oct 8, 2026AnnouncementThe Company announced that it has received approval to initiate the Phase 1/2 Strive™ clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia in Australia. Filing
  3. Aug 5, 2026LeadershipElliott Levy, M.D., a member of the Board of Directors of the Company who was serving as a class I director, resigned from the Board, effective August 4, 2026. Filing
  4. Jun 18, 2026VoteReported shareholder vote results. Filing
  5. May 26, 2026AgreementEditas Medicine, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC as representatives of the underwriters named therein, relating to an underwritten public offering of 55,555,556 shares of the Company’s common stock, $0.0001 par value per… Filing
  6. May 26, 2026AnnouncementEditas Medicine, Inc. notified TD Securities (USA) LLC that it was suspending and terminating the prospectus supplement, dated March 21, 2025, related to the sales agreement that the Company entered into with TD Cowen on May 14, 2021, as amended on February 28, 2024 and on March 5, 2025 (as… Filing
  7. May 26, 2026AnnouncementThe Company announced in an oral presentation at the 94 th European Atherosclerosis Society (EAS) Congress new preclinical data for EDIT-401, its lead in vivo development candidate, from preclinical studies in non-human primates. Filing
  8. May 14, 2026AnnouncementAt the 2026 Annual Meeting of the American Society of Gene and Cell Therapy, the Company reported new preclinical data supporting the continued advancement of the Company’s lead in vivo development candidate, EDIT-401, and its potential as a one-time treatment for hyperlipidemia, as well as the… Filing
  9. May 5, 2026ResultsReleased financial results. Filing
  10. Apr 7, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  11. Mar 27, 2026AnnouncementThe U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and… Filing
  12. Mar 9, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Editas Medicine financials

Famous investors that hold EDIT

4 of the 50 well-known investors we track reported holding EDIT in their latest 13F filing. The largest position is Jim Simons's, worth $6.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20262.50M$6.4M0.0%+1%
Steve Cohen · Point72 Asset ManagementQ3 2026512,506$1.3M0.0%+309%
Ken Griffin · Citadel AdvisorsQ3 2026234,312$602K0.0%+10%
Israel Englander · Millennium ManagementQ3 2026211,484$544K0.0%-58%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named EDIT in the last 120 days.

FiledHolderFormStake
Oct 27, 2026BlackRock, Inc.13G7.8%
Oct 27, 2026BlackRock, Inc.13G7.8%

Questions about Editas Medicine, Inc. (EDIT) stock

Who owns the most EDIT stock?

The largest reported owner of Editas Medicine, Inc. (EDIT) is TCG Crossover Management, LLC, with 11.3% of the company. In total, 213 funds and institutions reported holding EDIT at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are EDIT insiders buying or selling?

In the last 12 months, EDIT insiders reported no open-market purchases and 16 sales worth $177K. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in EDIT?

As of Oct 30, 2026, 38.72M EDIT shares were sold short, 25.2% of the shares outstanding, up 1.4% from the report before. At the average daily volume of 2.20M shares, buying them all back would take about 17.6 trading days (days to cover). See the history.

Which famous investors hold EDIT?

4 of the 50 well-known investors we track reported EDIT in their latest 13F filing, including Jim Simons, Steve Cohen, Ken Griffin. The largest position is worth $6.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.